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Abstract
Triglycerides are transported in plasma by specific triglyceride-rich lipoproteins; in epidemiologic 
studies, increased triglyceride levels correlate with higher risk for coronary artery disease (CAD). 
However, it is unclear whether this association reflects causal processes. We used 185 common 
variants recently mapped for plasma lipids (P<5×10−8 for each) to examine the role of 
triglycerides on risk for CAD. First, we highlight loci associated with both low-density lipoprotein 
cholesterol (LDL-C) and triglycerides, and show that the direction and magnitude of both are 
factors in determining CAD risk. Second, we consider loci with only a strong magnitude of 
association with triglycerides and show that these loci are also associated with CAD. Finally, in a 
model accounting for effects on LDL-C and/or high-density lipoprotein cholesterol, a 
polymorphism's strength of effect on triglycerides is correlated with the magnitude of its effect on 
CAD risk. These results suggest that triglyceride-rich lipoproteins causally influence risk for 
CAD.
Coronary artery disease (CAD) is one of the leading causes of death and infirmity 
worldwide1. Plasma lipids such as cholesterol and triglycerides are associated with risk for 
CAD. Cholesterol is mostly carried in either low-density lipoproteins (LDL) or high-density 
lipoproteins (HDL) whereas triglycerides are mostly transported in very low-density 
lipoproteins (VLDL), chylomicrons, and remnants of their metabolism.
In observational epidemiologic studies, plasma concentrations of increased triglycerides, 
increased LDL cholesterol (LDL-C), and decreased HDL cholesterol (HDL-C) are 
associated with increased risk for CAD2,3. However, it is difficult to establish causal 
inference from observational epidemiology4, especially given the correlations among 
triglycerides, LDL-C, and HDL-C3.
Single nucleotide polymorphisms (SNPs) can be used as instruments to test whether a 
biomarker causally relates to disease risk5,6. Because genotypes are randomly assigned at 
meiosis and fixed throughout lifetime, a genetic association may overcome some limitations 
of observational epidemiology such as confounding and reverse causation7,8. Using gene 
variants that exclusively affect a biomarker of interest (i.e., no pleiotropic effects on other 
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factors), investigators have confirmed LDL-C as a causal risk factor for CAD9 and have cast 
doubt on whether HDL-C directly influences risk for CAD10-15.
However, to date, it has been challenging to utilize a similar approach to define if plasma 
triglycerides reflect processes causal for CAD. In contrast to LDL-C and HDL-C, nearly all 
SNPs identified to date for plasma triglycerides have additional effects on either plasma 
LDL-C or HDL-C16-18, violating the “no pleiotropy” assumption of instrumental variable 
analysis8,19.
Here, we utilize common variants and develop a statistical framework to dissect causal 
influences among a set of correlated biomarkers. As this approach requires a large set of 
SNPs where precise measurements of effect on triglycerides, LDL-C, HDL-C, and CAD risk 
are simultaneously available, we leveraged: 1) 185 common SNPs all representing 
independent loci that are associated with at least one lipid trait at genome-wide levels of 
significance; 2) estimates of effect of each SNP on plasma triglycerides, LDL-C, and HDL-
C in a sample exceeding 180,000 individuals; and 3) estimates of effect of each SNP on 
CAD in a sample exceeding 86,000 individuals (22,233 cases and 64,762 controls).
We studied 185 SNPs at 157 one megabase pair intervals with association P<5×10−8 for 
triglycerides, LDL-C, or HDL-C in a meta-analysis involving 188,578 genotyped 
individuals (see companion manuscript20). For each SNP, we obtained effect estimates for 
triglycerides (βTRIGLYCERIDES), LDL-C (βLDL-C), and HDL-C (βHDL-C) (in standard 
deviation units and estimated using inverse normal transformed residuals of lipid levels after 
adjusting for covariates; see Supplementary Figure 1 for study design). We also estimated 
the effect of each SNP on CAD (βCAD) from a recently published genome-wide association 
study (GWAS) involving 86,995 individuals (the CARDIoGRAM study)21. For the 185 
SNPs, effect sizes (β) and P-values for triglycerides, LDL-C, HDL-C, and CAD are shown 
in Supplementary Table 1.
We considered several analytic approaches to investigate whether plasma triglycerides 
reflect processes causal for CAD. First, we evaluated the direction and magnitude of βLDL-C 
and βTRIGLYCERIDES in combination, and then compared these to βCAD (Figure 1 and 
Supplementary Figure 2). Second, to isolate the effect of triglycerides, from the 185 SNPs, 
we restricted analysis to loci that have moderate to strong effect on triglycerides (large 
βTRIGLYCERIDES) but minimal effect on LDL-C (small βLDL-C). Finally, across the 185 
SNPs, we formally developed and applied a statistical framework to test if the effect size of 
a SNP on triglycerides is linearly related to its effect size on CAD, before and after 
accounting for the same SNP's potential effect on plasma LDL-C and/or HDL-C.
For each of the 185 independent lipid SNPs, we evaluated joint patterns of associations for 
triglycerides and LDL-C by examining SNPs that have strong association to both 
triglycerides and LDL-C (P<5×10−8for each). Among these, we examined SNPs with the 
same direction and a similar magnitude of association for both lipid traits (within a factor of 
5). We observed 11 loci with this pattern of association. Five loci confer risk for CAD 
(P<0.05) and ten of the eleven loci show a direction of effect consistent between the lipid 
traits and CAD (Table 1). For example, the A allele at rs2954022 in the TRIB1 gene was 
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associated strongly with lower triglycerides (βTRIGLYCERIDES=−0.078, P=2×10−124) and 
lower LDL-C (βLDL-C=−0.055, P=4×10−51) and showed the expected association with lower 
CAD risk (βCAD=−0.056, P=6×10−5).
Next, we identified SNPs that had strong association with both triglycerides and LDL-C 
(P<5×10−8 for each) but had opposite directions for βTRIGLYCERIDES and βLDL-C (within a 
factor of 5, Table 2). Four SNPs displayed this pattern and none showed significant 
association with CAD (all P>0.05). For example, the A allele at rs2255141 in the GPAM 
gene was associated with lower triglycerides (βTRIGLYCERIDES=−0.021, P=1×10−8) and 
higher LDL-C (βLDL-C=0.030, P=7×10−14) but had no discernible effect on CAD risk (βCAD 
=−0.0076, P=0.63).
Secondly, we considered a subset of the 185 SNPs that have moderate to strong effects on 
triglycerides but minimal effect on LDL-C [n=44 SNPs, all SNPs have large 
βTRIGLYCERIDES (>0.01 or <−0.01) but small βLDL-C (between −0.01 and 0.01)]. In 
regression analysis, we confirmed that βLDL-C was not associated with βCAD for this set of 
SNPs (P=0.68; see Supplementary Table 2). However, we observed a significant association 
of βTRIGLYCERIDES and βCAD (P=3×10−5; see Supplementary Table 3). These observations 
suggest that the direction and magnitude of effect of a SNP on both triglycerides and LDL-C 
impact risk for CAD.
To formally investigate whether the strength of a SNP's association with triglycerides 
predicts CAD risk, we devised a statistical framework that controls for pleiotropic effects on 
secondary lipid traits. This approach is particularly important because SNP association 
signals with triglycerides, LDL-C, and/or HDL-C (βTRIGLYCERIDES, βLDL-C, and βHDL-C) 
are correlated (Supplementary Figure 3 and Supplementary Table 4).
We tested the role of triglycerides on CAD by first calculating residuals of βCAD after 
including as covariates βLDL-C and βHDL-C in our regression model (Supplementary Figure 
1). We then tested the association of βTRIGLYCERIDES with βCAD residuals. Similar models 
were created to assess the independent roles of LDL-C and HDL-C.
We observed that across the 185 SNPs, βLDL-C was strongly associated with βCAD, after 
adjusting for either βTRIGLYCERIDES individually, βHDL-C individually, or both 
βTRIGLYCERIDES and βHDL-C (all P < 1×10−18, Table 3). The pattern for βHDL-C was 
different. Across the 185 SNPs, βHDL-C was associated with βCAD, after adjusting for βLDL-C 
(P=0.005); however, this association was greatly attenuated after adjusting for 
βTRIGLYCERIDES individually (P=0.057) and rendered non-significant after accounting for 
both βTRIGLYCERIDES and βLDL-C (P=0.35, Table 3).
The results for triglycerides were similar to those observed for LDL-C. Across the 185 
SNPs, βTRIGLYCERIDES was strongly associated with βCAD, after adjusting for both βLDL-C 
and βHDL-C (P =1×10−9, Table 3).
As an alternative to this approach using residuals, we also tested a single model with the 
outcome variable of βCAD and predictor variables of βTRIGLYCERIDES, βLDL-C and βHDL-C 
considered jointly (Supplementary Table 5). Results were similar with βTRIGLYCERIDES and 
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βLDL-C showing association with βCAD (P=2×10−10 and P=1×10−22, respectively) but 
βHDL-C failing to show association (P=0.32).
In summary, we have demonstrated that: 1) SNPs with the same direction and a similar 
magnitude of association for both triglycerides and LDL-C tend to associate with CAD risk; 
2) loci that have an exclusive effect on triglycerides are also associated with CAD; and 3) 
the strength of a SNP's effect on triglycerides is correlated with the magnitude of its effect 
on CAD risk, even after accounting for the same SNP's effect on LDL-C and/or HDL-C.
Using an analytical approach that accounts for the potential pleiotropic effects of a SNP on 
triglycerides, LDL-C, and/or HDL-C, we provide evidence that plasma triglycerides likely 
reflects processes causal for CAD. This finding based on 185 common SNPs is in line with 
recent reports of specific genes predominantly related to triglycerides also affecting risk for 
CAD. A promoter SNP in the APOA5 gene22, a common SNP upstream of the TRIB1 
gene23, and a nonsense polymorphism at the APOC3 gene24 all predominantly associate 
with plasma triglycerides and each SNP has been convincingly related to clinical CAD11,25 
or subclinical atherosclerosis24.
Our results raise several questions. First, if plasma triglycerides reflect causal processes, 
what are the specific mechanistic direct links to atherosclerosis? Triglycerides are carried in 
plasma mostly in VLDL, chylomicrons and remnants of their metabolism and as such, 
triglycerides capture several physiologic processes that may promote atherosclerosis. One 
potential link is post-prandial cholesterol metabolism. Plasma triglycerides are highly 
correlated with the amount of cholesterol in remnant lipoproteins (i.e., VLDL and 
chylomicron particles after interaction with lipoprotein lipase) and a variety of evidence 
ranging from the human Mendelian disorder of Type III hyperlipoproteinemia to 
experimental evidence in cell culture and animal models suggests that cholesterol-rich 
remnant particles have pro-atherogenic properties similar to LDL (reviewed in 26). Another 
process reflected by plasma triglycerides is the activity of lipoprotein lipase, a key enzyme 
that hydrolyzes triglycerides within triglyceride-rich lipoproteins. Higher enzymatic activity 
of lipoprotein lipase in the circulation leads to lower plasma triglycerides; a gain-of-function 
nonsense polymorphism in the LPL gene has been shown to not only reduce plasma 
triglyceride levels but also lower risk for CAD27.
Second, why are plasma triglycerides not significantly associated with CAD in observational 
epidemiologic studies when multiple risk factors are considered jointly to predict risk for 
future CAD2? Multivariable models have known limitations for assessing the etiological 
relevance for a given exposure. For example, an exposure may be rendered non-significant 
after multivariable adjustment because of less precise measurement or greater biologic 
variability when compared with other factors. Plasma triglyceride measurements are more 
variable than other plasma lipids such as HDL-C26. Alternatively, downstream effects of an 
exposure may more completely capture the risk conferred. For example, body mass index 
does not predict CAD risk in the Framingham model after accounting for blood pressure and 
type 2 diabetes despite the accepted causal influence of weight on blood pressure and type 2 
diabetes28. Our approach using SNPs as proxies overcomes these limitations of 
observational epidemiology.
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Finally, what are the implications of these data for the development of drugs aimed at 
lowering plasma triglycerides with the hope of reducing CAD risk? Several recent 
randomized controlled trials have tested whether the lowering of plasma triglycerides with 
fish oils29 or with fibrates30-32 will decrease risk for CAD and in many cases, treatment did 
not reduce risk29,31,32. Possible explanations for failed trials are wrong study population, 
wrong mechanism of lowering triglycerides, insufficient degree of triglyceride-lowering, 
and limited statistical power.
Our study has several limitations. SNPs associated with triglycerides also relate to other 
lipid traits and thus, are not ideal instruments for Mendelian randomization analysis. Given 
that the plasma triglycerides measured in the blood is the end product of several metabolic 
processes, it is not surprising that triglyceride-related SNPs affect at least one other lipid 
trait. We have attempted to address this complexity through our statistical approach.
We are unable to distinguish if only specific mechanisms of altering triglycerides affect risk 
for CAD. Of note, there is strong evidence that at least three mechanisms that robustly 
influence triglycerides – loss of APOA5 function, loss of TRIB1 function, and gain of 
APOC3 function –increase risk for CAD.
In summary, we utilize common polymorphisms and employ a statistical framework to 
dissect causal influences among a set of correlated biomarkers. By applying this framework 
to a correlated set of plasma lipid measures and CAD risk, we suggest a causal role of 
triglyceride-rich lipoproteins in the development of CAD.
Online Methods
For the association of a given SNP with a plasma lipid trait, we obtained estimates of the 
effect size (βTRIGLYCERIDES, βLDL-C and βHDL-C) and strength of association (P-value) from 
a meta-analysis of association results from genome-wide and custom-array genotyping – the 
Global Lipids Genetics Consortium (GLGC) Metabochip study (described in companion 
manuscript, Willer et al.20). All effect sizes are in standard deviation units from inverse 
normal transformed residuals of lipids after adjusting for covariates. This analysis included 
up to 188,578 individuals from 60 studies. For the association of a given SNP with coronary 
artery disease (CAD), we obtained estimates of the effect size (βCAD) and strength of 
association (P-value) from a published GWAS study for CAD, the CARDIoGRAM study21. 
This study included 22,233 cases and 63,762 controls.
We selected independent SNPs associated with plasma lipids using the following criteria. 
First, we restricted to SNPs with association with at least one of the three lipid traits 
(triglycerides, LDL-C or HDL-C) at a genome-wide significance level of P<5×10−8. For 
each lipid locus – defined as a region of the genome that has a cluster of associated SNPs 
within one megabase from each other – we selected the strongest associated SNP (‘lead’ 
SNP). For loci with multiple associated SNPs, we calculated pairwise linkage disequilibrium 
(LD) estimates (r2) of these SNPs using whole genome sequencing data from 85 Utah 
residents with ancestryfrom northern and western Europe (CEU) samples from the 1000 
Genomes project33, and selected a second SNP if there was very low LD (r2<0.05) with the 
lead SNP. In total, we selected 185 SNPs that met these criteria. These criteria yield a 
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conservative estimate of the number of independent lipid SNPs. A list of effect sizes and P-
values for triglycerides, LDL-C, HDL-C and CAD for the 185 selected SNPs is shown in 
Supplementary Table 1.
To formally investigate whether the strength of a SNP's association with triglycerides 
predicts CAD risk, we performed linear regression on the effect sizes of each SNP for 
triglycerides (βTRIGLYCERIDES), LDL-C (βLDL-C), HDL-C (βHDL-C) as predictor variables, 
and the effect sizes of CAD (βCAD) as the outcome variable. To control for pleiotropic 
effects, we first calculated the residuals of βCAD after adjusting for covariates of 
βTRIGLYCERIDES, βLDL-C and/or βHDL-C. We then performed linear regression analysis in a 
second model on the effect size of the primary lipid trait (βTRIGLYCERIDES, βLDL-C or 
βHDL-C) with the residuals of βCAD. For example, to test for the role of LDL-C on CAD, we 
first calculated residuals of βCAD after including as covariates βTRIGLYCERIDES and βHDL-C 
in our regression model. In a second regression model, we then performed association of 
residual βCAD with βLDL-C. All possible combinations of linear regression analysis was 
performed between βTRIGLYCERIDES, βLDL-C or βHDL-C on βCAD (see Table 3).
As an alternative to this residuals approach, we also tested a single model where the 
outcome variable of βCAD was tested with the predictor variables of βTRIGLYCERIDES, 
βLDL-C and βHDL-C jointly considered (Supplementary Table 5). We also performed several 
sensitivity analyses to test for the effect of using different thresholds on βTRIGLYCERIDES 
and βLDL-C when highlighting loci with associations for both triglycerides and LDL-C 
(Supplementary Table 6, 7 and 8). We used thresholds that yielded the highest number of 
SNPs for each statistical analysis (factor threshold of 5 in Table 1 and Table 2, and β cutoff 
value of 0.01 in Supplementary Table 2 and 3). Furthermore, we assessed the effect of 
extreme influential outliers using Cook's D statistic34 (Supplementary Figure 4 and 
Supplementary Table 9) on our conditional regression models (Table 3). A list of the 
number of SNPs included in each of the different analyses are shown in Supplementary 
Table 10.
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Figure 1. Effect of a single nucleotide polymorphism on triglycerides, low-density lipoprotein 
cholesterol, and risk for coronary artery disease
Black dots represent SNPs with CAD P<0.001; B. Red dots represent SNPs with 0.01 < 
CAD P <0.001; C. Grey dots represent CAD P>0.10). Loci strongly associated with CAD 
tend to have consistent directions for both triglycerides and LDL-C (bottom left and top 
right quadrants). In contrast to the grey points, the black and red points are concentrated in 
the bottom left and top right quadrants. Betas are in standard deviation units. SNPs with 
−0.10<βLDL-C<0.10 and −0.10<βTRIGLYCERIDES<0.10 are shown.
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